Abbott Laboratories (ABT) shares closed at $103.09, rising 1.12% to outperform the broader market despite a downturn in major indices like the S&P 500 and Nasdaq. However, the stock has underperformed over the past month, falling 8.36% compared to a smaller decline for the Medical...
Abbott Laboratories (NYSE: ABT) is trading at a forward P/E of 17x, significantly below its $137.49 52-week high and the $116.54 analyst consensus target, despite posting four consecutive EPS beats. The market continues to price the stock as a slow-and-steady dividend stalwart with a beta...
Abbott Laboratories received FDA De Novo authorization for the Libre Duo, becoming the first company with a wearable device capable of continuously monitoring both glucose and ketone levels. This regulatory milestone targets an existing ecosystem of over 8 million users and aims to detect rising...
First Nebraska Trust Co acquired a new position in Abbott Laboratories (NYSE:ABT) during the first quarter, purchasing 5,959 shares valued at approximately $612,000. Several other hedge funds, including MidAtlantic Capital Management Inc., Cornerstone Financial Management LLC, and Purpose Unlimited Inc., also established or modified new...
Equities analysts have issued mixed but generally positive signals regarding Abbott Laboratories (NYSE:ABT) ahead of its FY2027 earnings. Erste Group Bank lifted its full-year EPS estimate to $6.06, while JPMorgan Chase raised its price target to $120 and maintained an 'overweight' rating. Conversely, Bank of...
